about
A clinician's guide to biosimilars in oncologyChemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumoursA phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer.A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma.Automated prognostic pattern detection shows favourable diffuse pattern of FOXP3(+) Tregs in follicular lymphoma.Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK centerA study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity.Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B-cell lymphoma.Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom.Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.QuantiGene Plex Represents a Promising Diagnostic Tool for Cell-of-Origin Subtyping of Diffuse Large B-Cell Lymphoma.Primary cilia are increased in number and demonstrate structural abnormalities in human cancer.An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity.Epidural meningioma of the sacral canal. Case report.Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International ExtranBendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.PLK1 and YY1 interaction in follicular lymphoma is associated with unfavourable outcome.A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma.Guidelines for the management of diffuse large B-cell lymphoma.Drug-Induced Interstitial Lung Disease: A Systematic ReviewIdentification of unfavourable paired cell interactions in follicular lymphoma using hypothesized interaction distribution (HID) analysisYY1 expression predicts favourable outcome in follicular lymphoma
P50
Q26748410-790B6E8C-3C69-4F46-99BA-4BF2B733AFB6Q30315150-A36B2165-8131-450F-A161-4F231FDDA783Q31151258-47B955A2-0FDD-4025-A2A0-E2531DC8664FQ33367359-F1B86AA7-13DD-484B-9158-7E53C6BC7DD6Q33440715-CA121D05-1814-44C8-BA01-F0247F841477Q34627911-ECEFD2C8-9688-4CAA-90B2-04F3C61641F3Q36287398-A5F9C4A1-1752-49A1-9252-5D16749175B1Q36862523-D2AFDCD0-8251-4A4D-8302-ACE24005FB48Q37322979-44570BFA-2DA2-4C74-B62A-9962B739DBB3Q38373698-9F9BE504-B38A-4084-BE77-24512ADAB5C2Q38404561-48B7B56F-9716-424B-9D77-69A1ADAAC2B4Q38600671-86E53F97-6BE7-48D8-B0A9-4CCE79C1CAA6Q38743903-60F27B8F-36AC-41A9-9962-36537550247FQ39938060-79D3A27A-DC05-433D-B0A0-981F746E7E43Q40930934-B0D805AB-B7F7-4C89-8E49-6B9D4872B366Q42502077-F386660D-F468-4D91-9CC5-C90B2D11F8C2Q42706225-51E862BD-1042-4092-B3EC-27112FD12A2FQ47601148-ADD4F106-383B-4FA5-8F80-C5A7461BEE5FQ48008882-2A7EE5F6-B4B8-41F0-851E-C260FDA7B280Q48146418-9D0CCBA9-2DA9-4389-99B1-9D24E444B8DDQ48559035-86ABFBC9-671B-47AE-A9AD-90B5DD18C8B2Q50916979-8AA29EC7-1447-402D-88C4-B8B3E3C74002Q54287946-378ECD90-6706-48B7-A0A7-07D1CAB3A06EQ54708579-05479E19-71DD-4DBD-9D5E-6358E4304D9BQ57463653-F6CD036A-4268-4984-AA94-87A388038541Q59306329-6E9EF057-DD16-4ED5-9178-94A73CF4619CQ59306343-41D2D50C-33E9-4A76-B14F-8C5C3C8C42D8
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kim Linton
@ast
Kim Linton
@en
Kim Linton
@es
Kim Linton
@nl
Kim Linton
@sl
type
label
Kim Linton
@ast
Kim Linton
@en
Kim Linton
@es
Kim Linton
@nl
Kim Linton
@sl
prefLabel
Kim Linton
@ast
Kim Linton
@en
Kim Linton
@es
Kim Linton
@nl
Kim Linton
@sl
P1053
O-9903-2015
P106
P1153
14119919500
P31
P3829
P496
0000-0002-3294-1548